150 related articles for article (PubMed ID: 18061443)
21. Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic pain.
Biswas K; Aya T; Qian W; Peterkin TA; Chen JJ; Human J; Hungate RW; Kumar G; Arik L; Lester-Zeiner D; Biddlecome G; Manning BH; Sun H; Dong H; Huang M; Loeloff R; Johnson EJ; Askew BC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4764-9. PubMed ID: 18706809
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
Xiong Y; Ullman B; Choi JS; Cherrier M; Strah-Pleynet S; Decaire M; Dosa PI; Feichtinger K; Teegarden BR; Frazer JM; Yoon WH; Shan Y; Whelan K; Hauser EK; Grottick AJ; Semple G; Al-Shamma H
J Med Chem; 2010 Aug; 53(15):5696-706. PubMed ID: 20684606
[TBL] [Abstract][Full Text] [Related]
23. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain.
Huang H; Player MR
J Med Chem; 2010 Aug; 53(15):5383-99. PubMed ID: 20369879
[No Abstract] [Full Text] [Related]
24. Novel small molecule bradykinin B1 receptor antagonists. Part 1: benzamides and semicarbazides.
Schaudt M; Locardi E; Zischinsky G; Stragies R; Pfeifer JR; Gibson C; Scharn D; Richter U; Kalkhof H; Dinkel K; Schnatbaum K
Bioorg Med Chem Lett; 2010 Feb; 20(3):1225-8. PubMed ID: 20015645
[TBL] [Abstract][Full Text] [Related]
25. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
[TBL] [Abstract][Full Text] [Related]
26. Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain.
Campos MM; Leal PC; Yunes RA; Calixto JB
Trends Pharmacol Sci; 2006 Dec; 27(12):646-51. PubMed ID: 17056130
[TBL] [Abstract][Full Text] [Related]
27. Novel small molecule bradykinin B1 receptor antagonists. Part 2: 5-membered diaminoheterocycles.
Zischinsky G; Stragies R; Schaudt M; Pfeifer JR; Gibson C; Locardi E; Scharn D; Richter U; Kalkhof H; Dinkel K; Schnatbaum K
Bioorg Med Chem Lett; 2010 Feb; 20(3):1229-32. PubMed ID: 20015651
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a potent, non-peptide bradykinin B1 receptor antagonist.
Su DS; Markowitz MK; DiPardo RM; Murphy KL; Harrell CM; O'Malley SS; Ransom RW; Chang RS; Ha S; Hess FJ; Pettibone DJ; Mason GS; Boyce S; Freidinger RM; Bock MG
J Am Chem Soc; 2003 Jun; 125(25):7516-7. PubMed ID: 12812482
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.
Hilfiker MA; Wang N; Hou X; Du Z; Pullen MA; Nord M; Nagilla R; Fries HE; Wu CW; Sulpizio AC; Jaworski JP; Morrow D; Edwards RM; Jin J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4292-5. PubMed ID: 19487124
[TBL] [Abstract][Full Text] [Related]
30. 3-Methoxylphenylpropyl amides as novel receptor subtype-selective melatoninergic ligands: characterization of physicochemical and pharmacokinetic properties.
Zhu J; Hu Y; Ho MK; Wong YH
Xenobiotica; 2011 Jan; 41(1):35-45. PubMed ID: 21110748
[TBL] [Abstract][Full Text] [Related]
31. 3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.
Chen JJ; Nguyen T; D'Amico DC; Qian W; Human J; Aya T; Biswas K; Fotsch C; Han N; Liu Q; Nishimura N; Peterkin TA; Yang K; Zhu J; Riahi BB; Hungate RW; Andersen NG; Colyer JT; Faul MM; Kamassah A; Wang J; Jona J; Kumar G; Johnson E; Askew BC
Bioorg Med Chem Lett; 2011 Jun; 21(11):3384-9. PubMed ID: 21514825
[TBL] [Abstract][Full Text] [Related]
32. Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition.
Su J; Cui M; Tang Y; Zhou H; Liu L; Dong Q
Biochem Biophys Res Commun; 2009 Oct; 388(2):205-11. PubMed ID: 19647718
[TBL] [Abstract][Full Text] [Related]
33. 2' biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling.
Budzik B; Garzya V; Shi D; Walker G; Lauchart Y; Lucas AJ; Rivero RA; Langmead CJ; Watson J; Wu Z; Forbes IT; Jin J
Bioorg Med Chem Lett; 2010 Jun; 20(12):3545-9. PubMed ID: 20483599
[TBL] [Abstract][Full Text] [Related]
34. Preparation and optimization of a series of 3-carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists.
Dressen D; Garofalo AW; Hawkinson J; Hom D; Jagodzinski J; Marugg JL; Neitzel ML; Pleiss MA; Szoke B; Tung JS; Wone DW; Wu J; Zhang H
J Med Chem; 2007 Oct; 50(21):5161-7. PubMed ID: 17880055
[TBL] [Abstract][Full Text] [Related]
35. 2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists.
Feng DM; Wai JM; Kuduk SD; Ng C; Murphy KL; Ransom RW; Reiss D; Chang RS; Harrell CM; MacNeil T; Tang C; Prueksaritanont T; Freidinger RM; Pettibone DJ; Bock MG
Bioorg Med Chem Lett; 2005 May; 15(9):2385-8. PubMed ID: 15837330
[TBL] [Abstract][Full Text] [Related]
36. Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists.
Ahmed M; Briggs MA; Bromidge SM; Buck T; Campbell L; Deeks NJ; Garner A; Gordon L; Hamprecht DW; Holland V; Johnson CN; Medhurst AD; Mitchell DJ; Moss SF; Powles J; Seal JT; Stean TO; Stemp G; Thompson M; Trail B; Upton N; Winborn K; Witty DR
Bioorg Med Chem Lett; 2005 Nov; 15(21):4867-71. PubMed ID: 16143522
[TBL] [Abstract][Full Text] [Related]
37. Small molecule bradykinin B1 receptor antagonists as potential therapeutic agents for pain.
Chen JJ; Biswas K
Prog Med Chem; 2008; 46():173-204. PubMed ID: 18381126
[No Abstract] [Full Text] [Related]
38. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
[TBL] [Abstract][Full Text] [Related]
39. Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.
D'Amico DC; Aya T; Human J; Fotsch C; Chen JJ; Biswas K; Riahi B; Norman MH; Willoughby CA; Hungate R; Reider PJ; Biddlecome G; Lester-Zeiner D; Staden CV; Johnson E; Kamassah A; Arik L; Wang J; Viswanadhan VN; Groneberg RD; Zhan J; Suzuki H; Toro A; Mareska DA; Clarke DE; Harvey DM; Burgess LE; Laird ER; Askew B; Ng G
J Med Chem; 2007 Feb; 50(4):607-10. PubMed ID: 17243660
[TBL] [Abstract][Full Text] [Related]
40. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
